Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Lhommé C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL, Lentz MA, Van Glabbeke M, Matthieu-Boué A, Mignard D, Chevallier B. Lhommé C, et al. Among authors: mignard d. J Clin Oncol. 1999 Oct;17(10):3136-42. doi: 10.1200/JCO.1999.17.10.3136. J Clin Oncol. 1999. PMID: 10506610 Clinical Trial.
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Bécouarn Y, Gamelin E, Coudert B, Négrier S, Pierga JY, Raoul JL, Provençal J, Rixe O, Krisch C, Germa C, Bekradda M, Mignard D, Mousseau M. Bécouarn Y, et al. Among authors: mignard d. J Clin Oncol. 2001 Nov 15;19(22):4195-201. doi: 10.1200/JCO.2001.19.22.4195. J Clin Oncol. 2001. PMID: 11709562 Clinical Trial.
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Ychou M, Douillard JY, Rougier P, Adenis A, Mousseau M, Dufour P, Wendling JL, Burki F, Mignard D, Marty M. Ychou M, et al. Among authors: mignard d. Am J Clin Oncol. 2000 Apr;23(2):143-8. doi: 10.1097/00000421-200004000-00008. Am J Clin Oncol. 2000. PMID: 10776974 Clinical Trial.
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.
Boige V, Taïeb J, Hebbar M, Malka D, Debaere T, Hannoun L, Magherini E, Mignard D, Poynard T, Ducreux M. Boige V, et al. Among authors: mignard d. Eur J Cancer. 2006 Mar;42(4):456-9. doi: 10.1016/j.ejca.2005.09.034. Epub 2006 Jan 20. Eur J Cancer. 2006. PMID: 16427779 Clinical Trial.
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V. Freyer G, et al. Among authors: mignard d. Br J Cancer. 2000 Aug;83(4):431-7. doi: 10.1054/bjoc.2000.1303. Br J Cancer. 2000. PMID: 10945486 Free PMC article. Clinical Trial.
[Charcot-Marie-Tooth disease associated with periaxin mutations (CMT4F): Clinical, electrophysiological and genetic analysis of 24 patients].
Renouil M, Stojkovic T, Jacquemont ML, Lauret K, Boué P, Fourmaintraux A, Randrianaivo H, Tallot M, Mignard D, Roelens P, Tabailloux D, Bernard R, Cartault F, Chane-Thien E, Dubourg O, Ferrer X, Sole G, Fournier E, Latour P, Lacour A, Mignard C. Renouil M, et al. Among authors: mignard d. Rev Neurol (Paris). 2013 Aug-Sep;169(8-9):603-12. doi: 10.1016/j.neurol.2013.07.004. Epub 2013 Sep 5. Rev Neurol (Paris). 2013. PMID: 24011642 French.
16 results